Gujarat Kidney IPO Allotment Status 2025: Check Result, Refunds & Listing

The Gujarat Kidney & Super Speciality IPO is an upcoming mainboard book-built IPO that was open for subscription from December 22, 2025 to December 24, 2025. The issue size is ₹250.80 crore and the shares are slated to be listed on both BSE and NSE. Investors who applied for this IPO are now awaiting the allotment result.

🔍 Gujarat Kidney IPO Allotment Status

The Gujarat Kidney IPO allotment is expected to be finalized on Friday, December 26, 2025. Once finalized, applicants can check their allotment status via the official registrar link below:

Status: ALLOTMENT PENDING / UPCOMING

Refunds and credit of shares to demat accounts are expected on December 29, 2025. The shares are scheduled to list on December 30, 2025 on both stock exchanges.

📌 Gujarat Kidney IPO Details

  • Issue Size: ₹250.80 crore
  • Price Band: ₹108 – ₹114 per share
  • Lot Size: 128 shares
  • Minimum Retail Investment: ₹14,592
  • Face Value: ₹2 per share
  • Issue Type: Book-Building IPO
  • Listing: BSE, NSE
  • Registrar: MUFG Intime India Pvt. Ltd.

📅 IPO Timeline

IPO Open DateDec 22, 2025
IPO Close DateDec 24, 2025
Allotment DateDec 26, 2025
Refunds / Demat CreditDec 29, 2025
Listing DateDec 30, 2025

🏢 About Gujarat Kidney & Super Speciality Ltd.

Gujarat Kidney & Super Speciality Ltd., incorporated in 2019, is a multispeciality healthcare provider operating seven hospitals and four pharmacies across Gujarat. With a total bed capacity of nearly 500 beds, the company specializes in renal sciences, urology, and super-speciality surgical procedures, supported by an experienced team of doctors and medical staff.

The company has shown strong financial performance, with significant growth in revenue, profitability, and efficiency metrics. Its focus on specialised services has positioned it well within Gujarat’s healthcare ecosystem.

Bookmark this page to get the latest updates on the Gujarat Kidney IPO allotment status, refunds, and stock exchange listing performance.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top